CN108699149B - 抗-ror1抗体及其用途 - Google Patents

抗-ror1抗体及其用途 Download PDF

Info

Publication number
CN108699149B
CN108699149B CN201780009313.5A CN201780009313A CN108699149B CN 108699149 B CN108699149 B CN 108699149B CN 201780009313 A CN201780009313 A CN 201780009313A CN 108699149 B CN108699149 B CN 108699149B
Authority
CN
China
Prior art keywords
ror1
binding protein
binding
sample
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780009313.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699149A (zh
Inventor
阿什维尼·巴拉克里什南
本杰明·G·霍夫斯特伦
朱莉·伦道夫-哈贝克
斯坦利·R·瑞德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CN108699149A publication Critical patent/CN108699149A/zh
Application granted granted Critical
Publication of CN108699149B publication Critical patent/CN108699149B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780009313.5A 2016-02-02 2017-02-02 抗-ror1抗体及其用途 Active CN108699149B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662290337P 2016-02-02 2016-02-02
US62/290,337 2016-02-02
US201662324876P 2016-04-19 2016-04-19
US62/324,876 2016-04-19
PCT/US2017/016300 WO2017136607A1 (en) 2016-02-02 2017-02-02 Anti-ror1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN108699149A CN108699149A (zh) 2018-10-23
CN108699149B true CN108699149B (zh) 2023-01-06

Family

ID=58054529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780009313.5A Active CN108699149B (zh) 2016-02-02 2017-02-02 抗-ror1抗体及其用途

Country Status (9)

Country Link
US (3) US10968275B2 (cg-RX-API-DMAC7.html)
EP (2) EP3411408B1 (cg-RX-API-DMAC7.html)
JP (2) JP7029401B2 (cg-RX-API-DMAC7.html)
CN (1) CN108699149B (cg-RX-API-DMAC7.html)
AU (1) AU2017213844A1 (cg-RX-API-DMAC7.html)
CA (1) CA3012827A1 (cg-RX-API-DMAC7.html)
ES (1) ES2903228T3 (cg-RX-API-DMAC7.html)
MX (1) MX2018009011A (cg-RX-API-DMAC7.html)
WO (1) WO2017136607A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
EP3411408B1 (en) 2016-02-02 2021-12-08 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
BR112020002368A2 (pt) 2017-08-07 2020-09-01 Nbe-Therapeutics Ag conjugados anticorpo-medicamento tendo alta tolerabilidade in vivo
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
EP3936523A4 (en) * 2019-01-08 2022-09-07 Shenzhen University ANTIBODY DETECTION OF MALIGNANT TUMOR CELLS AND THEIR APPLICATIONS
BR112021014833A2 (pt) 2019-01-29 2021-10-05 Juno Therapeutics, Inc. Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023186100A1 (zh) * 2022-04-02 2023-10-05 山东先声生物制药有限公司 抗ror1的抗体及其用途
WO2024025343A1 (ko) * 2022-07-26 2024-02-01 (주)에임드바이오 항-ror1 항체 및 이의 용도
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN115894691A (zh) * 2022-12-27 2023-04-04 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
AU2023418243A1 (en) * 2022-12-27 2025-08-14 Sph Biotherapeutics (Hk) Limited Antigen-binding protein targeting ror1
CN116183472B (zh) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Cba法检测非人类灵长类动物细胞因子的验证方法
WO2025007910A1 (en) * 2023-07-04 2025-01-09 TJ Biopharma (Shanghai) Co., Ltd. Anti-ror1 antibodies and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA114536A (en) 1908-09-18 1908-10-13 Adolphe Chalas Nickel recovering process
CA138293A (en) 1911-11-06 1912-02-06 Charles E. Archie Variable speed gearing
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
US20070274981A1 (en) 2003-10-16 2007-11-29 Imclone Systems Incorporation Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
DK2305300T3 (en) 2008-07-10 2016-06-06 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
JP6277126B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体
JO3625B1 (ar) 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
IL237315B (en) 2012-08-20 2022-07-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
ES2992753T3 (en) 2012-08-24 2024-12-17 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2014164554A1 (en) 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
AU2015339402B2 (en) 2014-10-27 2021-08-26 Fred Hutchinson Cancer Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
WO2016115559A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
EP3411408B1 (en) 2016-02-02 2021-12-08 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy;Amir H. DaneshManesh 等;《Int. J. Cancer》;20080610;第123卷;第1190-1195页 *
Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies;Jiahui Yang 等;《PLOS ONE》;20110630;第6卷(第6期);第1-15页 *

Also Published As

Publication number Publication date
JP7029401B2 (ja) 2022-03-03
US11932691B2 (en) 2024-03-19
WO2017136607A1 (en) 2017-08-10
CN108699149A (zh) 2018-10-23
US10968275B2 (en) 2021-04-06
EP3411408B1 (en) 2021-12-08
AU2017213844A1 (en) 2018-08-02
EP3411408A1 (en) 2018-12-12
JP2019511904A (ja) 2019-05-09
JP2022028918A (ja) 2022-02-16
CA3012827A1 (en) 2017-08-10
US20190040132A1 (en) 2019-02-07
US20240352119A1 (en) 2024-10-24
MX2018009011A (es) 2018-11-19
US20210147540A1 (en) 2021-05-20
EP4006056A1 (en) 2022-06-01
ES2903228T3 (es) 2022-03-31

Similar Documents

Publication Publication Date Title
US20240352119A1 (en) Anti-ror1 antibodies and uses thereof
US11155632B2 (en) Anti-CD47 monoclonal antibody and use thereof
CN108373504B (zh) Cd24特异性抗体和抗cd24-car-t细胞
US12492252B2 (en) Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
CN110088137A (zh) 针对mica和micb蛋白的抗体
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
CN111454358A (zh) 一种嵌合抗原受体及其应用
EP4303234A1 (en) Antibody against nkp46 and application of antibody
CN117529337A (zh) 针对dll3的结合分子及其应用
WO2022099126A1 (en) Anti-psma antibodies and methods of use
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
HK40075786A (en) Anti-ror1 antibodies and uses thereof
HK40000385B (en) Anti-ror1 antibodies and uses thereof
EP4328243A1 (en) Asymmetric antibody with improved cytotoxicity against cancer cell
US20240174741A1 (en) Il-38-specific antibodies
JP7209284B2 (ja) Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法
HK40048285B (en) Anti-human program death factor-1 monoclonal antibody
HK40048285A (en) Anti-human program death factor-1 monoclonal antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Fred Hutchinson Cancer Center

Address before: Washington State

Applicant before: Seattle Cancer Care Alliance

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220927

Address after: Washington State

Applicant after: Seattle Cancer Care Alliance

Address before: Washington State

Applicant before: FRED HUTCHINSON CANCER RESEARCH CENTER

GR01 Patent grant
GR01 Patent grant